Convulsive Status Epilepticus Not Controlled After Second-Line Therapy
Clinical Scenario
Convulsive status epilepticus has continued despite a second-line agent given in the 20–40 minute treatment window. Seizures remain active at the 40-minute mark — the threshold that defines failure of the second therapy phase and triggers escalation.
The clinical goal throughout remains the same: termination of convulsive status epilepticus.
Previous Line — Goal Not Reached
A single second-line agent — fosphenytoin, valproic acid, or levetiracetam (IV phenobarbital as an alternative when the others are unavailable) — did not terminate convulsive status epilepticus by the 40-minute mark. This unmet endpoint is what triggers this protocol.
Third Therapy Phase — Partial Overview
From the 40-minute mark onward, the approach shifts. One pathway at this stage involves anesthetic-class agents administered under continuous EEG monitoring. The complete set of options, decision criteria, and sequencing is contained in the full structured protocol.
References
DOI: 10.5698/1535-7597-16.1.48
- The third therapy phase should begin when the seizure duration reaches 40 minutes.
- Thus, if second therapy fails to stop the seizures, treatment considerations should include repeating second-line therapy or anesthetic doses of either thiopental, midazolam, pentobarbital, or propofol (all with continuous EEG monitoring).
View source ↗